Ketamine and Liver Function Tests: Monitoring LFTs During Therapy

Ketamine and liver function tests monitoring LFTs during therapy go together because the liver metabolizes nearly the entire administered dose of ketamine, regardless of whether it is given orally, sublingually, or intravenously. Low-dose ketamine used for depression, chronic pain, or other approved indications carries a substantially lower hepatotoxicity risk than recreational or chronic high-dose use, but elevated liver enzymes have still been documented in a subset of treated patients. Baseline liver function panels before treatment starts, paired with a defined testing schedule during acute and maintenance phases, let clinicians catch hepatic stress early and adjust dosing before it becomes a bigger problem.

How Ketamine Affects the Liver

Ketamine undergoes N-demethylation in the liver to form norketamine, its primary active metabolite, which retains about one-third of ketamine's NMDA receptor antagonist activity. Norketamine is further broken down into hydroxynorketamine and dehydronorketamine, both of which are conjugated and cleared through the kidneys. The liver processes the full administered dose no matter how ketamine is given, but the route changes how much of that dose passes through the liver on the first pass. Intravenous ketamine bypasses first-pass metabolism and produces lower initial hepatic exposure per dose. Oral ketamine goes through significant first-pass metabolism, which raises hepatic exposure even though systemic bioavailability drops to roughly 17-20%. Sublingual dosing is partially absorbed through the mouth's mucous membranes, which reduces first-pass metabolism compared with swallowed oral doses.

According to Mayo Clinic, a normal alanine aminotransferase (ALT) level typically falls between 7 and 56 units per liter, and clinicians generally treat values above three times that upper limit as a signal to slow down or pause treatment. LFT monitoring exists to catch that kind of change before it becomes clinically significant liver injury.

Risk Factors for Ketamine-Related Liver Injury

Several factors raise the likelihood of ketamine-related liver injury, and clinicians weigh them together rather than in isolation:

• Duration of therapy: cumulative exposure over months to years is the strongest risk factor
• Dose and frequency: higher doses and more frequent administration increase hepatic burden
• Pre-existing liver disease: cirrhosis, hepatitis, fatty liver disease, or other hepatic conditions
• Concurrent hepatotoxic medications: acetaminophen, certain antibiotics, statins, and anticonvulsants
• Drug interactions: CYP3A4 inhibitors such as ketoconazole or grapefruit juice can raise ketamine plasma levels and hepatic exposure, so reviewing a patient's full medication list matters as much as reviewing ketamine dosing (see our guide to ketamine drug interactions)
• Alcohol use: concurrent or recent heavy alcohol use compounds hepatic risk, covered in more detail in our guide on ketamine and alcohol interaction safety
• Age: geriatric patients may have reduced hepatic reserve

Baseline Liver Testing Before Treatment

Before starting ketamine therapy, clinicians typically order a full hepatic function panel. For a plain-language breakdown of what each marker measures, see MedlinePlus's overview of liver function tests:

• ALT (alanine aminotransferase): the most specific marker for hepatocellular injury
• AST (aspartate aminotransferase): elevated in liver injury but also released from muscle, heart, and red blood cells
• ALP (alkaline phosphatase): elevated in cholestatic, or bile duct, injury patterns
• GGT (gamma-glutamyl transferase): confirms a hepatic origin for elevated ALP and is also sensitive to alcohol use
• Total and direct bilirubin: reflects hepatic excretory function and rises with significant liver impairment
• Albumin: reflects synthetic liver function; low values suggest chronic liver disease
• PT/INR: a sensitive marker of hepatic synthetic capacity

Baseline abnormalities change the risk-benefit calculation before treatment starts. ALT or AST under three times the upper limit of normal (ULN) is generally acceptable to proceed with closer monitoring. Values between three and five times ULN call for extreme caution, and clinicians often consider alternative treatments or wait for normalization. ALT or AST above five times ULN is generally treated as a contraindication until liver function improves. Elevated bilirubin or low albumin suggests more significant hepatic dysfunction and typically warrants a gastroenterology consultation before proceeding.

What Abnormal LFTs Mean During Therapy

Ketamine-associated liver injury typically shows up as a hepatocellular pattern, meaning ALT rises more than ALP. Mild elevation, ALT under three times ULN, appears in an estimated 5 to 10% of patients on maintenance low-dose ketamine. It is often transient and self-limiting, and clinicians usually recheck in 2 to 4 weeks; if the value is stable or falling, therapy continues with ongoing monitoring.

Moderate elevation, ALT between three and five times ULN, generally leads to a dose reduction or a temporary treatment hold. Clinicians rule out other causes such as new medications, alcohol use, viral hepatitis, or biliary disease, then recheck in 1 to 2 weeks. Treatment resumes at a lower dose only after values fall back below three times ULN.

Severe elevation, ALT above five times ULN, calls for stopping ketamine immediately, an urgent gastroenterology or hepatology consultation, and a full workup for alternative causes. Ketamine should not restart without specialist clearance.

Managing LFT Elevations and Special Populations

When LFT elevations are linked to ketamine, clinicians generally follow a stepwise approach: reduce the dose by 25-50% and recheck LFTs in 2 weeks, extend dosing intervals (for example, from twice weekly to once weekly), or consider a route change, since switching from oral to sublingual or intravenous dosing can lower first-pass hepatic exposure. Our complete guide to ketamine dosage covers how dosing intervals and routes affect a patient's overall exposure. If moderate elevations persist despite dose reduction, treatment is typically held for 2 to 4 weeks and rechecked; if elevations still don't resolve, discontinuation follows.

No hepatoprotective agent has been validated specifically for ketamine-associated liver injury. General supportive measures include limiting other hepatotoxic medications, avoiding alcohol during treatment, and staying adequately hydrated to support hepatic and renal clearance. N-acetylcysteine has been used anecdotally in some cases, though evidence specific to ketamine hepatotoxicity is lacking.

Patients with nonalcoholic fatty liver disease, chronic hepatitis, or compensated cirrhosis may still be candidates for low-dose ketamine when the clinical need is significant. These patients typically start at 50-75% of the standard dose, get LFTs checked every 2 weeks during the acute phase, and obtain baseline hepatology clearance before starting. Patients with substance use histories, particularly alcohol use disorder, may have subclinical liver damage that baseline testing alone won't reveal, so a broader hepatic assessment, including imaging, is often warranted. Patients taking other hepatically metabolized psychiatric medications, such as valproic acid or certain atypical antipsychotics, add to the cumulative hepatic burden that clinicians need to track alongside ketamine.

Clear documentation matters too: baseline and serial LFT results, the reasoning behind any dose changes, and communication with other prescribers involved in a patient's care all help keep long-term monitoring consistent.